<DOC>
	<DOCNO>NCT01304784</DOCNO>
	<brief_summary>This study open-label , dose-escalation study MM-111 five different combination treatment main goal determine safety MM-111 combination .</brief_summary>
	<brief_title>A Study MM-111 Combination With Multiple Treatments Patients With HER2 Positive Cancer</brief_title>
	<detailed_description>To determine MTD DLT MM 111 administer combination either 1 ) cisplatin , capecitabine , trastuzumab ; 2 ) lapatinib +/- trastuzumab ; 3 ) paclitaxel trastuzumab 4 ) lapatinib , paclitaxel trastuzumab 5 ) docetaxel trastuzumab patient human epidermal growth factor receptor ( HER2+ ) solid tumor</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>Inclusion Criteria Patients must histologically cytologically confirm advanced cancer positive HER2 , either : At least 3+ positive immunohistochemistry , Gene amplify positive fluorescence situ hybridization ( FISH ) . Chromogenic situ hybridization ( CISH ) acceptable confirm HER2 positivity FISH result available . The patient 's cancer must recur progress follow standard therapy respond standard therapy . ( Patients previously untreated HER2+ metastatic gastric gastroesophageal junction cancer enrol onto cisplatin , capecitabine , trastuzumab + MM111 arm study . ) Patients must ≥ 18 year age . Patients legal representative must able understand sign inform consent . Patients evaluable measurable disease ≥ 1 cm . Patients must ECOG PS ≤ 1 Karnofsky performance score ≥ 70 . Patients must adequate hematologic status evidence : Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 Platelet count ≥ 100,000 platelets/mm3 Hemoglobin ≥ 9 g/dL For arm 1 , 2 , 3 4 patient must adequate hepatic function evidence : Serum total bilirubin ≤ 1.5 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ≤ 2.5 x ULN ( 5 × ULN acceptable liver metastasis present ) For arm 5 ( Docetaxel ) patient must adequate hepatic function evidence : Serum bilirubin within normal limit , AST and/or ALT &lt; 1.5 X ULN alkaline phosphatase &lt; 2.5 X ULN concomitantly elevate Patients must adequate renal function evidence : Serum creatinine ≤ 1.5 × ULN Calculated clearance 60 mL/min/1.73 m2 patient creatinine level institutional normal Patients must recover effect prior surgery , radiotherapy antineoplastic therapy . National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE v.4.0 ) Grade 1 acceptable patient preexist peripheral neuropathy . Patients must life expectancy least 3 month . Women childbearing potential well fertile men partner must agree abstain sexual intercourse use effective form contraception study 60 day follow last dose MM111 . Patients potentially curative antineoplastic therapy available Patients pregnant lactate Patients active infection unexplained fever &gt; 38.5°C screen visit first schedule day dose . ( At discretion Investigator , patient tumor fever may enrol . ) Patients untreated and/or symptomatic primary metastatic central nervous system ( CNS ) malignancy ( Patients CNS metastases undergone surgery radiotherapy , whose disease stable , stable dose corticosteroid least 2 week prior first schedule day dose eligible trial . ) Patients know hypersensitivity component MM111 hypersensitivity reaction fully human monoclonal antibody . Patients known history hypersensitivity drug component particular regimen . Patients receive recent antitumor therapy include : Investigational therapy administer within 28 day prior first schedule day dose MM111 . Dosing &lt; 28 day since receive investigational therapy acceptable time interval equal least five halflives investigational agent pass . Any standard chemotherapy radiation within 14 day ( passed time actual anticipated toxicity ) prior first schedule dose MM111 . There necessary washout trastuzumab . Patients enrol lapatinibcontaining arm study need washout period lapatinib . Patients New York Heart Association ( NYHA ) Class III IV congestive heart failure leave ventricular ejection fraction ( LVEF ) &lt; 50 % History myocardial infarction within 12 month enrollment Uncontrolled hypertension ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 100 mm Hg ) Known angina pectoris require medication Known clinically significant valvular heart disease Known history highrisk arrhythmias Known history congestive heart failure Lack physical integrity upper gastrointestinal tract malabsorption syndrome Active gastrointestinal bleedingPatients receive prior maximum cumulative anthracycline dos : doxorubicin liposomal doxorubicin dose &gt; 360 mg/m2 mitoxantrone &gt; 120 mg/m2 idarubicin &gt; 90 mg/m2 epirubicin dose high 720 mg/m2 Other ( e.g. , liposomal doxorubicin anthracycline equivalent 360 mg/m2 doxorubicin ) If 1 anthracycline use , cumulative dose must exceed equivalent 360mg/m2 doxorubicin Patients history allogeneic transplant . ( Patients history autologous bone marrow stem cell transplant may enrol . ) Patients know human immunodeficiency virus ( HIV ) , hepatitis B C. ( If patient previously treat hepatitis C undetectable viral load , consider eligible trial . ) Patients medical psychological condition , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>Failed least one line standard therapy</keyword>
</DOC>